Tehran University of Medical Sciences

Science Communicator Platform

Share By
Immunological Risk Factors for Recurrent Implantation Failure Using a Deep Learning Model: A Multicenter Retrospective Cohort Study Publisher Pubmed



Dashti M ; Ghasemzadeh A ; Doustfateme S ; Daraei M ; Danaii S ; Najdi N ; Berjis K ; Heris JA ; Chakarikhiavi F ; Karimi S ; Rahimifar S ; Davoodi S ; Baharaghdam S ; Bolouri N Show All Authors
Authors
  1. Dashti M
  2. Ghasemzadeh A
  3. Doustfateme S
  4. Daraei M
  5. Danaii S
  6. Najdi N
  7. Berjis K
  8. Heris JA
  9. Chakarikhiavi F
  10. Karimi S
  11. Rahimifar S
  12. Davoodi S
  13. Baharaghdam S
  14. Bolouri N
  15. Jafarisavari Z
  16. Ardehaie RM
  17. Amir A
  18. Yousefi M

Source: Scientific Reports Published:2025


Abstract

Despite advancements in assisted reproductive technology (ART), recurrent implantation failure (RIF) continues to pose a significant challenge to achieving pregnancy. We included 2,463 retrospective RIF patients with no gynecological and anatomical anomalies who were referred to a clinical immunologist and received targeted immunotherapies. Twenty-three variables were used to develop a deep learning (TabNet) model to predict live births. Statistical analyses were used to compare characteristics between live birth and implantation failure groups. Model performance was evaluated using a confusion matrix, the receiver operating characteristic (ROC) curve, and calibration plots. Our model showed an accuracy of 87.4% and an AUROC of 0.952. According to the model, when there were no missing input variables, the most important features were age, Th1/Th2 ratio, BMI, anti-thyroid peroxidase (anti-TPO), antinuclear antibodies (ANA), anti-dsDNA, and anti-tissue transglutaminase (anti-TTG), respectively. In conclusion, the TabNet model yielded strong performance in predicting live births in RIF patients using a combination of 23 variables. This model can help improve understanding of the underlying mechanism of implantation failure and stratify patients who may benefit from immune modulation interventions. © The Author(s) 2025.